Meetings - The ASCO Post

This is Part 3 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Dr...

gynecologic cancers

/ Targeted Treatment Options in Platinum-Resistant Ovarian Cancer

Case 2: HER2-Positive Platinum-Resistant Ovarian Cancer

This is Part 2 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Dr...

gynecologic cancers

/ Targeted Treatment Options in Platinum-Resistant Ovarian Cancer

Case 1: FRα-Positive, High-Grade, Platinum-Resistant Ovarian Cancer

This is Part 1 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Dr...

Targeted Treatment Options in Platinum-Resistant Ovarian Cancer

Case 3: Low-Grade Platinum-Resistant Ovarian Cancer

Case 2: HER2-Positive Platinum-Resistant Ovarian Cancer

Case 1: FRα-Positive, High-Grade, Platinum-Resistant Ovarian Cancer

Short-Term Hormonal Treatment Offers Early Insight Into Tumor Behavior and Resistance for ER-HER2 Breast Cancer

Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Immune Checkpoint Inhibitors, Cardiovascular Health, and a Potentially Protective Biomarker

Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

LLS Unveils Name Change